Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
24 mai 2024 16h15 HE
|
Sobi, Inc.
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03 août 2023 07h05 HE
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
03 mai 2022 08h00 HE
|
Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Imago BioSciences to Host Virtual Investor Event
01 déc. 2021 08h00 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
10 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
11 juin 2021 09h00 HE
|
Constellation Pharmaceuticals , Inc.
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
31 mai 2021 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 07h00 HE
|
Constellation Pharmaceuticals , Inc.
Dosing underway in the Phase 3 MANIFEST-2 clinical trialRecommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohortsUpcoming data presentation at ASCO...
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
07 janv. 2021 09h30 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...